83 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Novartis' Asthma Candidate Fails in LUSTER Phase III Studies http://www.zacks.com/stock/news/675066/novartis-asthma-candidate-fails-in-luster-phase-iii-studies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-675066 Dec 17, 2019 - Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685884 Dec 24, 2019 - Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
3 Rare Disease Drug Launches to Watch in 2020 https://www.fool.com/investing/2019/12/27/4-rare-disease-drug-launches-to-watch-in-2020.aspx?source=iedfolrf0000001 Dec 27, 2019 - Patients who inherit life-threatening blood disorders have some important new treatment options.
A $20 Billion Sweet Spot in Biotech https://www.fool.com/investing/2019/12/28/a-20-billion-sweet-spot-in-biotech.aspx?source=iedfolrf0000001 Dec 28, 2019 - Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
Are Investors Undervaluing Aegon NV (AEG) Right Now? http://www.zacks.com/stock/news/696275/are-investors-undervaluing-aegon-nv-aeg-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-696275 Dec 31, 2019 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb http://www.zacks.com/research-daily/709865/top-analyst-reports-for-novartis-mcdonalds-bristol-myers-squibb?cid=CS-ZC-FT-research_daily-709865 Jan 09, 2020 - Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS http://www.zacks.com/stock/news/711468/the-zacks-analyst-blog-highlights-novartis-mcdonalds-bristol-myers-squibb-cme-and-ubs?cid=CS-ZC-FT-press_releases-711468 Jan 10, 2020 - The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
Novartis' Heart Drug Gets Accelerated Review in Britain for High-Risk Patients https://www.fool.com/investing/2020/01/13/novartis-heart-drug-gets-accelerated-review-in-bri.aspx?source=iedfolrf0000001 Jan 13, 2020 - Cholesterol-lowering inclisiran could be available in the country as early as 2021.
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis https://www.fool.com/investing/2020/01/14/abbvie-and-boehringer-ingelheims-skyrizi-beat-nova.aspx?source=iedfolrf0000001 Jan 14, 2020 - The results should help the upstart drug to compete with Cosentyx.
Novartis Starts 2020 a Step Ahead of Other Big Pharmas with the Most Newly Approved Drugs https://www.fool.com/investing/2020/01/15/novartis-starts-2020-a-step-ahead-of-other-big-pha.aspx?source=iedfolrf0000001 Jan 15, 2020 - New treatments for breast cancer, multiple sclerosis, and others make the drugmaker's stock a more compelling buy in 2020.

Pages: 1234567...9

<Page 2>